NUCLIDIUM AG, a clinical-stage radiopharmaceutical company, announced that first clinical data from its ongoing Phase I/II trial has been selected for an oral presentation at the European Association of Nuclear Medicine (EANM) congress. The trial is evaluating the company's copper-based PET tracer, 61Cu-TraceNet™ [61Cu]Cu-NODAGA-LM3, for the detection of SSTR-positive gastroenteropancreatic and bronchopulmonary neuroendocrine tumors (GEP & BP-NETS).
Clinical Trial Presentation at EANM 2025
Dr. Guillaume Nicolas, Deputy Head of Nuclear Medicine at the Department of Theragnostics, University Hospital Basel, Switzerland, and principal investigator of the study, will present the preliminary results from the COPPER PET in NET Trial. The presentation is scheduled for Monday, October 6, 2025, at 9:45 AM CEST at the Barcelona International Convention Centre Room 117.
The abstract, titled "A phase I/II study of [61Cu]Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET Trial," has been selected as a top-rated oral presentation in the Clinical Oncology Track under the Oncology & Theranostics Committee: NET Imaging session.
Copper-Based Theranostic Platform
NUCLIDIUM is pioneering the development of next-generation copper-based radiopharmaceuticals for cancer diagnosis and treatment. The company's differentiated platform leverages copper isotopes, utilizing Copper-61 for diagnostics and Copper-67 for therapeutics, with the potential to overcome existing limitations in radiotheranostics.
The company's operations span Switzerland and Germany, combining innovative chemistry, deep clinical expertise, and strategic manufacturing capabilities to deliver scalable, accessible, and clinically superior theranostic solutions. NUCLIDIUM is committed to expanding the reach and efficacy of radiotheranostics, including addressing critical unmet medical needs in oncology and women's health.
Company Leadership
The clinical-stage biotechnology company is led by CEO Leila Jaafar, PhD, who is driving the development of the proprietary copper-based theranostic platform. The company's approach aims to create more accessible and effective diagnostic and therapeutic options for cancer patients worldwide.
